GlaxoSmithKline Inc. v. Canada (Attorney General) et al., (2005) 334 N.R. 324 (FCA)
Linked as:
Extract
GlaxoSmithKline Inc. v. Canada (Attorney General) et al., (2005) 334 N.R. 324 (FCA)
No longer available (Autolink)
See the full content of this document
This document cites
- Eli Lilly Canada Inc. v. Canada (Minister of Health), (2002) 225 F.T.R. 110 (TD)
- Hoffmann-La Roche Ltd. et al. v. Canada (Minister of National Health and Welfare) et al., (1995) 193 N.R. 394 (FCA)
- Hoffmann-La Roche Ltd. et al. v. Canada (Minister of National Health and Welfare) et al., (1995) 97 F.T.R. 288 (TD)
- GlaxoSmithKline Inc. v. Canada (Attorney General) et al., (2004) 263 F.T.R. 142 (FC)
- Glaxo Group Ltd. et al. v. Novopharm Ltd. et al., (1998) 144 F.T.R. 252 (TD)
